The Liver Cancer Program at the Icahn School of Medicine at Mount Sinai is situated in New York City, the most ethnically diverse city in the United States. Our Center sits on the edge of Harlem, a community with a predominantly Afro-American and Hispanic population in which the incidence of HCC approaches 20 per 100,000, similar to that observed in high-incidence countries like China. Mount Sinai has developed an extensive outreach program that conducts screening and surveillance throughout our catchment area in underserved communities including neighborhoods with predominantly Chinese, Pakistani, and Egyptian populations as well as in Harlem. We have a long-standing interest in liver cancer at Mount Sinai that dates back to the creation of the specialty of Hepatology by Mount Sinai icons Hans Popper and Fenton Schaffner, which was accelerated greatly with the creation of the Liver Transplant Program, the first in New York State, in 1988.
The Icahn School of Medicine at Mount Sinai has been at the forefront of clinical management of HCC in the United States for at least 20 years, owing in large part to the unique talents of the Hepatobiliary Surgery Unit led by Myron Schwartz, MD, along with members of the Divisions of Oncology and Liver Diseases, Pathology, and Radiology. Our institution ranks first in regional inpatient market share for HCC; Mount Sinai Hospital is, in fact, the leading center in the US in the number of new HCC patients evaluated annually, approximately 400 in 2013. This program initially earned its international reputation as a consequence of the clinical contributions made in the area of the surgical management of HCC, combined with the growth of its liver transplantation program and the burgeoning clinical and research activities of the Division of Liver Diseases, a separate Division in the Department of Medicine distinct from the Gastroenterology Division. In parallel, Josep M. Llovet MD, joined the Mount Sinai faculty in 2004 following a sabbatical at our institution and established the basis for the clinical and translational research of the program.